Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Guangbin Peng

1PUBLICATIONS

16CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (1)

Sort by Publication Date:

|Mar 31, 2023

Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.

David S Hong, Michael Postow, Bartosz Chmielowski

Pageof 1

Frequent Collaborators

1 joint publications

David S Hong

1 joint publications

Michael Postow

1 joint publications

Bartosz Chmielowski

1 joint publications

Ryan Sullivan

1 joint publications

Amita Patnaik

1 joint publications

Ezra E W Cohen

1 joint publications

Geoffrey Shapiro

1 joint publications

Conor Steuer

1 joint publications

Martin Gutierrez

1 joint publications

Heather Yeckes-Rodin

Frequent Collaborators

1 joint publications

David S Hong

1 joint publications

Michael Postow

1 joint publications

Bartosz Chmielowski

1 joint publications

Ryan Sullivan

Top Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

See more related videos

Top Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

See more related videos